Thymmune Therapeutics Inc.
Cambridge, MA
- UEI
- SRWAYANF8K28
- CAGE
- 93ZF3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 215 First St #401, Cambridge, MA 02142, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a stem-cell derived thymic cell therapy to treat patients with athymia | National Institute of Allergy and Infectious Diseases (NIH) | $6,773,454 |
Quick answers
Is Thymmune Therapeutics Inc. registered in SAM.gov?
Yes. Thymmune Therapeutics Inc.'s SAM.gov registration is active through May 19, 2027.
What is Thymmune Therapeutics Inc.'s most recent federal award?
Thymmune Therapeutics Inc.'s most recent federal grant award is Development of a stem-cell derived thymic cell therapy to treat patients with athymia (R44AI170266), from National Institute of Allergy and Infectious Diseases (NIH), on April 15, 2022.
On GovTribe
See Thymmune Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors